| Similar Articles |
|---|
 |
Chemistry World
September 18, 2013
Sonja Hampel |
Beetle feet inspire drug delivery patches A drug delivery plaster mimicking the wet adhesion of beetle feet has been developed by scientists in Taiwan.   |
Chemistry World
December 17, 2010
James Mitchell Crow |
Drug delivery: from needles to nanorods? Gold nanorods warmed by beams of infrared light could be the ideal way to deliver drugs through the skin, researchers in Japan have discovered. |
Chemistry World
December 12, 2011
James Urquhart |
Silk delivers drugs without the pain Silk's multifunctional properties could offer a safe and pain-free way to administer drugs and vaccines, as well as store drugs without the need for refrigeration. |
Technology Research News
December 3, 2003 |
Microneedles give painless shots The smaller the hypodermic needle, the less it hurts when it pierces skin. Researchers demonstrated that an array of 400 microneedles can be used to pierce human skin, and successfully used a similar micro array to deliver insulin to diabetic rats. |
Chemistry World
January 7, 2011
Russell Johnson |
Sticky hydrogels make resilient wound dressings An adhesive material made from a hydrogel filled with nanoparticles could lead to wound dressings that won't fall off when you sweat. |
American Family Physician
September 15, 2000 |
The Nicotine Patch How do I use the patch?... What do I need to tell my doctor before I use the patch?... My skin tingles under the patch. Is that normal?... Can I wear the patch in the shower?... What if the patch falls off?... |
Chemistry World
June 2011 |
Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress |
American Family Physician
December 15, 2004
Pamela Dull |
STEPS The transdermal patch of oxybutynin is no more effective than the short- or long-acting oral form. The patch costs more, but causes less dry mouth. Skin reactions will cause about 10 percent of patients to stop using it. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
American Family Physician
July 1, 2002
Suriti Kundu |
Principles of Office Anesthesia: Part II. Topical Anesthesia The development of topical anesthetics has provided the family physician with multiple options in anesthetizing open and intact skin. |
Pharmaceutical Executive
October 1, 2006
Jason McKinnie |
Smaller is Better Everybody has heard about using nanotechnology in drug delivery, but not many people - even specialists in drug development - know quite where the new technology fits in. |
Chemistry World
July 23, 2012
Jennifer Newton |
Delivering insulin in a skin cream Scientists in Japan have developed a way to administer insulin to patients through the skin. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
September 4, 2007
Rich Duprey |
Pain in Mylan's Future Competition for painkiller patch may prove to be a major pain for the generics maker Mylan. The stock has dropped precipitously from its highs, and while it's recovered some, its immediate outlook is cloudy. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
May 27, 2010
Brian Orelli |
This Rabid Agency Could Permanently Damage Your Portfolio The FDA has gotten a little out of control. The wonkiness of the FDA's actions makes it hard for investors to figure out what the agency will do. |
The Motley Fool
June 8, 2010
Brian Orelli |
Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
Chemistry World
January 16, 2008
Jonathan Edwards |
Microneedles May Mean an End to Painful Injections Microneedles that could deliver drugs painlessly can be made more quickly and cheaply thanks to a laser polymerisation technique developed by US scientists. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
Chemistry World
June 22, 2015
Manisha Lalloo |
'Smart patch' set to deliver for diabetes patients A research team has created patches that release insulin in response to changes in oxygen brought about by high glucose levels and hope this could lead to a smarter, painless way of treating the disease. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
AskMen.com
Dustin Driver |
Common Skin Disorders The following skin afflictions are usually embarrassing and sometimes very serious. Thankfully, with a little help from your doctor, they can be treated and managed. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
